First AD

Second AD

Evan Y. Yu, MD, is section head of Medical Oncology and a professor in the Clinical Research Division at the Fred Hutchinson Cancer Center; medical director of Clinical Research Support at Fred Hutchinson/University of Washington (UW)/Seattle Children’s Cancer Consortium; and the assistant fellowship director and a professor in the Division of Hematology and Oncology at UW Medicine

The expert panel discusses how treatment strategies change based on cisplatin eligibility and the role of maintenance therapy.

Cisplatin Eligibility and Maintenance Therapy in Metastatic Urothelial Carcinoma

Genitourinary Cancers

EXE-22-OSD1273 - /clinical/genitourinary-cancer

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research. 

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Advancing Treatments for Bladder Cancer: Insights from ASCO GU 2024

Peer Exchange

Fox Chase Cancer Center

Cancer Centers

Partner

Huntsman Cancer Institute at the University of Utah 

University of North Carolina, Lineberger Comprehensive Cancer Center

Fred Hutch Cancer Center

The expert panel discusses how treatment strategies change based on cisplatin eligibility and the role of maintenance therapy in metastatic urothelial carcinoma.